Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

Affiliations

• ¹ Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
• ² Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ³ Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
• ⁴ IRCCS Humanitas Clinical and Research Center & Humanitas University, Department of Biomedical Sciences, via Manzoni 56, 20089, Rozzano, Milan, Italy.
• ⁵ Departments of Pathology & Laboratory Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.
• ⁶ Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
• ⁷ David Steensma LLC, Cambridge, Massachusetts 02139, USA.
• ⁸ Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
• ⁹ Health Research Institute La Fe, Valencia, Spain; Hospital Universitario y Politécnico La Fe, Valencia, Spain; CIBERONC, IS Carlos III, Madrid, Spain.
• ¹⁰ Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY, USA.
• ¹¹ Leipzig University Hospital, Leipzig, Germany.
• ¹² Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
• ¹³ Leukemia Program, University of Chicago Medicine and University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
• ¹⁴ Department of Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
• ¹⁵ Division of Hematology, Department of Medicine, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Palo Alto, CA, USA.
• ¹⁶ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹⁷ National Cancer Institute, Cancer Therapy Evaluation Program, Rockville, MD, USA.
• ¹⁸ Precision BioSciences, Inc., Durham, NC, USA.
• ¹⁹ Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
• ²⁰ Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, and Myeloid Malignancies Program, National Institutes of Health, Bethesda, MD, 20892, USA.
• ²¹ Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
• ²² Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.
• ²³ Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
• ²⁴ Division of Hematology, Department of Medicine, Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
• ²⁵ Hôpital Saint Louis, Assistance Publique Hôpitaux de Paris and Paris Cité University, Paris, France.
• ²⁶ Italian Group for Adult Hematologic Diseases (GIMEMA), Health Outcomes Research Unit, Rome, Italy.
• ²⁷ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA.
• ²⁸ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ²⁹ Department of Hematology, Oncology, and Palliative Care, Carbone Cancer Center, The University of Wisconsin-Madison, Madison, WI, USA.
• ³⁰ Leukemia Program, Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
• ³¹ Department of Medical Oncology/ Hematology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
• ³² Leukemia Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
• ³³ Blood Cancer UK Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
• ³⁴ Ohio State University Comprehensive Cancer Center/ James Cancer Hospital, Ohio State University, Columbus, OH, USA.
• ³⁵ Division of Hematology and Oncology, Moores Cancer Center, UC San Diego, La Jolla, CA, USA.
• ³⁶ University of Rochester Medical Center, Department of Pathology and Laboratory Medical Center, Rochester, NY, USA.
• ³⁷ Department of Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research and University of Melbourne, Victoria, Australia.
• ³⁸ MDS Unit, Hematology, AOUC, University of Florence, Italy.
• ³⁹ Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA. Electronic address: [email protected].